Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone...

Area of Science:

• Bone biology
• Endocrinology
• Pharmacology

Background:

• Calcimimetics reduce parathyroid hormone (PTH) in secondary hyperparathyroidism.
• The direct impact of calcimimetics on bone cells expressing the calcium-sensing receptor (CaSR) remains unclear.

Purpose of the Study:

• To investigate the direct effects of calcimimetics on bone cells via CaSR activation.
• To evaluate the in vitro and in vivo bone effects of a specific calcimimetic (AMG 641).

Main Methods:

• Utilized a rat model with and without uremia, employing total parathyroidectomy and continuous PTH infusion to establish a PTH clamp.
• Administered a calcimimetic (AMG 641) or vehicle to assess bone parameters.
• Conducted in vitro studies using an osteosarcoma cell line and human bone marrow mesenchymal stem cells.

Main Results:

• Calcimimetic treatment increased osteoblast number and osteoid volume in normal rats under PTH clamp.
• In uremic rats, calcimimetics decreased plasma PTH and enhanced osteoblast number, osteoid surface, and bone formation at higher PTH levels.
• In vitro, the calcimimetic promoted osteogenic gene expression, Erk1/2 phosphorylation, and osteogenic differentiation of stem cells.

Conclusions:

• Calcimimetic administration exerts a direct anabolic effect on bone.
• This anabolic bone effect counterbalances the reduction in PTH levels caused by calcimimetics.
• Findings suggest a direct therapeutic potential of calcimimetics on bone health beyond PTH suppression.